Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Age dependency of doxorubicin clearance in children with leukemia and solid tumors
ISRCTN57509500Phase 2Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Jan 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in leukemia, Acute Leukaemia, B-cell chronic lymphocytic leukemia (B-CLL) and 8 more, sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoints: Age dependency of doxorubicin pharmacokinetics and Pharmacokinetic dataset completeness. Started Jan 2011; status: completed.
02
Drugs
doxorubicin
03
Conditions
leukemiaAcute LeukaemiaB-cell chronic lymphocytic leukemia (B-CLL)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ISRCTN57509500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN57509500.